Ivemend (fosaprepitant)
- Region
- 🇪🇺 EU
- Active substance
- fosaprepitant
- Company
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- Therapeutic area
- Vomiting; Cancer
- EU approval
- Fri 11 Jan 2008
- Application
- EMEA/H/C/000743
- ATC
- A04AD12
- Official record
- www.ema.europa.eu
Indication
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is given as part of a combination therapy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇺🇸 Navitrux Approved · Avyxa Holdings
Follow Ivemend
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.